Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: Genetic and physiological evidence

• Published in: Circulation (New York, N.Y.) Vol. 108; no. 24; pp. 3042 - 3047
• Main Authors: DAYOUB, Hayan, ACHAN, Vinod, COOKE, John P, ADIMOOLAM, Shanthi, JACOBI, Johannes, STUEHLINGER, Marcus C, WANG, Bing-Yin, TSAO, Philip S, VALLANCE, Patrick, KIMOTO, M, PATTERSON, Andrew J
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 16.12.2003; American Heart Association, Inc
• Subjects: Amidohydrolases - genetics; Amidohydrolases - metabolism; Animals; Arginine - analogs & derivatives; Arginine - blood; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Cells, Cultured; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Endothelium - metabolism; Hemodynamics; Humans; Medical sciences; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitric Oxide - biosynthesis; Nitric Oxide Synthase - metabolism; Transfection; blood pressure; endothelium; Enzyme; risk faclors; vasodilation; Nitric oxide; Hydrolases; Cardiovascular disease; Dimethylargininase
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/01.CIR.0000101924.04515.2E

NO is a major regulator of cardiovascular physiology that reduces vascular and cardiac contractility. Accumulating evidence indicates that endogenous inhibitors may regulate NOS. The NOS inhibitors asymmetric dimethylarginine (ADMA) and N-monomethylarginine are metabolized by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). This study was designed to determine if increased expression of DDAH could reduce tissue and plasma levels of the NOS inhibitors and thereby increase NO synthesis. We used gene transfer and transgenic approaches to overexpress human DDAH I in vitro and in vivo. The overexpression of DDAH in cultured endothelial cells in vitro induced a 2-fold increase in NOS activity and NO production. In the hDDAH-1 transgenic mice, we observed approximately 2-fold increases in tissue NOS activity and urinary nitrogen oxides, associated with a 2-fold reduction in plasma ADMA. The systolic blood pressure of transgenic mice was 13 mm Hg lower than that of wild-type controls (P<0.05). The systemic vascular resistance and cardiac contractility were decreased in response to the increase in NO production. DDAH I overexpression increases NOS activity in vitro and in vivo. The hDDAH-1 transgenic animal exhibits a reduced systolic blood pressure, systemic vascular resistance, and cardiac stroke volume. This study provides compelling evidence that the elaboration and metabolism of endogenous ADMA plays an important role in regulation of NOS activity.